Variable

Univariate

Multivariate

HR (CI 95%)

p value

HR (CI 95%)

p value

Sex

0.88 (0.51 - 1.54)

0.65

-

-

Age (≤60 vs >60 years)

0.65 (0.39 - 1.09)

0.10

-

-

Cirrhosis (yes vs no)

0.99 (0.31 - 3.19)

0.99

-

-

Prior totreatmentSorafenib

1.42 (0.84 - 2.38)

0.18

Child-Pugh (B vs A)

1.24 (0.56 - 2.75)

0.59

ECOG-PS (2 vs <2)

2.45 (1.01 - 5.91)

0.04

BCLC (C vs B)

1 (0.52 - 1.93)

0.99

Numbers of nodules (3 vs ≤3)

0.67 (0.36 - 1.26)

0.21

Major nodule (≥2 vs <2 cm)

0.24 (0.08 - 0.67)

<0.01

Extrahepatic metastasis (yes vs no)

1.31 (0.79 - 2.17)

0.29

Vascular invasion (yes vs no)

1.23 (0.71 - 2.14)

0.46

AFP (≤100 vs >100 ng/mL)

2.91 (1.31 - 6.48)

<0.01

3.16 (1.56 - 6.41)

<0.01

Dermatologic adverse event (yes vs no)

0.35 (0.2 - 0.62)

<0.01

0.44 (0.23 - 0.83)

<0.01

Diarrhea adverse event (yes vs no)

0.53 (0.32 - 0.9)

<0.01

-

-

Time of sorafenib (≤6 vs >6 months)

0.28 (0.16 - 0.5)

<0.01

0.25 (0.14 - 0.46)

<0.01